Corporate healthcare conglomerates are deep pockets. It wouldn't surprise me in the least to see a buyout offer by a suitor the size of a J&J or Abbott trying snatch up the company once they certify to detect E. Coli.
There is crazy leverage here against the status quo, and a wholesale-acquisition arrangement might make sense given that laser backscatter cell counters and ID software are in use for other purposes. It's not a huge stretch to imagine some of the IP being contested at some point. Having a large-cap legal department on board could also come in handy for protecting the IP against infringement abroad. In return, a large-scale corporate entity could implement the IP quickly and tap into a solid revenue stream with minimal competition, effectively locking in new market cap.
Reading about Brennan's previous endeavors, his inside ownership, and how he and Frank have certainly put their money on the line to continue this company, all point to the continued development of the MIT-1000. I would compare the MIT-1000 vs. conventional testing leverage to the relationship between Microsoft and Royal typewriters in the early 80's. If the business interests package and promote the technology effectively, it should represent a de facto leap forward in a vital sector.
Just thinking in pixels. I'm sure a few here will want to yammer away about no sales, no revenues, no hope-in-hell. Tell it to AOAC or NAMSA. This is high risk, but I'll be tempted to bite at my target price. We're close.